Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Berkbigler

Orthopaedic Surgery Farmington, MO Doctor of Osteopathy

NPI 1295983567 CMS profile 286001

606 Maple Valley Dr, Farmington, MO 63640

Open in the dashboard

General payments

$6,906

117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,600 paid to institutions, not to them · program years 2022–2023

Through program year 2025, Thomas Berkbigler of Farmington, MO is reported in the CMS Open Payments database as having received $6,906 across 117 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $23,600 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 63rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $347 7
2024 General $1,548 12
2023 General $514 10
2022 General $2,368 26
2021 General $315 19
2020 General $211 12
2019 General $1,603 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Berkbigler
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Thomas Berkbigler were reported at $347. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Thomas Berkbigler Orthopaedic Surgery median Middle half National median
2019 $1,603 $644 $140–$2,844 $163
2020 $211 $312 $75–$1,860 $114
2021 $315 $520 $117–$2,495 $132
2022 $2,368 $598 $128–$2,731 $149
2023 $514 $461 $128–$2,264 $160
2024 $1,548 $497 $134–$2,475 $164
2025 $347 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medacta USA, Inc. $2,230 14 payments
  2. Sonex Health, Inc. $1,543 16 payments
  3. Arthrex, Inc. $1,018 3 payments
  4. Zimmer Biomet Holdings, Inc. $517 16 payments
  5. Amgen Inc. $246 13 payments
  6. Elite Orthopedics, LLC $211 7 payments
  7. Flexion Therapeutics, Inc. $178 12 payments
  8. Stryker Corporation $149 2 payments
  9. DePuy Synthes Sales Inc. $145 5 payments
  10. FX Shoulder USA, Inc $139 3 payments
  11. Other $530 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,075 100 payments
  2. Travel and Lodging $2,841 16 payments
  3. Education $990 1 payment
Products named General payments · program years 2019–2025
  1. ULTRAGUIDECTR $1,538 15 payments
  2. ULTRAGUIDETFR $1,529 14 payments
  3. AMIStem H Femoral Stems $888 5 payments
  4. GMK SPHERE Knee $513 2 payments
  5. GMK Sphere Revision System $503 3 payments
  6. EVENITY $246 13 payments
  7. Prolia $246 13 payments
  8. GMK Sphere Orthopedics/Orthopedic Surgery $180 2 payments
  9. Zilretta $178 12 payments
  10. mymobility Platform $149 1 payment
  11. Other $1,930 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

280

Median for Orthopedic Surgery: 203

Drug cost

$1,776

Median for Orthopedic Surgery: $1,433

Branded share of claims

28.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 63 $889
Oxycodone Hcl Generic 91 $368
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 68 $236
Ondansetron Odt Ondansetron Brand 13 $124
Ibuprofen Generic 13 $76
Gabapentin Generic 18 $48
Tramadol Hcl Generic 14 $35

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 118 billing codes

Paid by Medicare

$149,398

Of which drugs: $23,633

Medicare patients

363

Average age 74

Services billed

4,058

220 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Diabetes 38%
Ischemic heart disease 35%
Depression 28%
Chronic kidney disease 26%
Atrial fibrillation 25%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 11 896 $11,995
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 14 1,344 $9,342
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 36 83 $417
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 74 476 $324
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 41 48 $39

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $21
$21 — 896
Exparel
  • Pacira Pharmaceuticals Incorporated $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record